$COSM

Noble Capital initiated coverage on Cosmos Health (NASDAQ: COSM) with an outperform rating and a $1.40 price target, citing potential profitability improvements from higher-margin products. The stock is currently at $0.26, down 74% over the past year. The firm highlights the company's wholesale distribution and expanding U.S. direct-to-consumer operations as growth drivers.

Cosmos Health (COSM) launched e-commerce and subscription services in Australia, New Zealand, and Oceania. The company reported 8,940 active U.S. subscriptions and 14,624 online orders. CEO Greg Siokas highlighted the success of the subscription model. Cosmos Health manufactures and distributes pharmaceutical and nutraceutical products.

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days · Q4 2026 U.S. revenue: approximately $15 million e

Cosmos Health Inc. (NASDAQ: COSM) reported record revenue growth in 2026, with preliminary nine-month revenue of $54.3 million, up 19% year-over-year. CEO Greg Siokas highlighted strong performance across all business segments, including a rapidly growing U.S. direct-to-consumer subscription model and a sixfold increase in contract manufacturing pipeline. The company expects full-year 2026 revenue to exceed $74 million, with significant contributions from both established and new segments.

Cosmos Health (NASDAQ:COSM) projects $15M in Q4 2026 U.S. revenue with a 70% gross margin. Subscriptions, at 8,940 active, are expected to generate 75% of revenue. The company anticipates daily sales to rise from $60,000 to over $200,000 by year-end, with active subscriptions exceeding 40,000.

Cosmos Health (COSM) reported 6,287 active U.S. subscriptions, with 60.5% of checkout orders including a subscription. The subscriptions average 2.4 units and carry a monthly value of $919,945. The company plans to expand the subscription model to other brands and markets. Figures are preliminary and unaudited.

Cosmos Health Inc. (NASDAQ: COSM) reported record U.S. direct-to-consumer sales exceeding $92,000 on October 11, 2026, with $902,000 in sales over the past 30 days. Average daily sales over the past 10 days doubled to over $60,000, approaching the company's annual target of over $23 million in U.S. revenue. The company is evaluating extending this model to additional brands and markets.

Cosmos Health reported preliminary nine-month 2026 revenue of $54.3M, up 19% YoY, with Q3 revenue at $17.4M, a record. The company reaffirmed its full-year 2026 revenue outlook of over $90M, citing growth across all segments and record production and distribution milestones.

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million ● Record nine-month revenue of approximately $54.3 million — up 19%

Cosmos Health Inc. (NASDAQ: COSM) reported its portfolio of 15+ proprietary brands and 10 branded generics, sold in 40+ countries. The company targets markets estimated at $946B in 2025, with products in nutraceuticals, infection control, advanced formulations, and skin care. Key brands include Sky Premium Life, C-Scrub, and NOOR, with gross margins over 70%. Manufacturing occurs at GMP-certified facilities in Europe and the U.S.